JOP20200281A1 - مركبات أريل غير متجانسة رباعية الحلقة - Google Patents

مركبات أريل غير متجانسة رباعية الحلقة

Info

Publication number
JOP20200281A1
JOP20200281A1 JOP/2020/0281A JOP20200281A JOP20200281A1 JO P20200281 A1 JOP20200281 A1 JO P20200281A1 JO P20200281 A JOP20200281 A JO P20200281A JO P20200281 A1 JOP20200281 A1 JO P20200281A1
Authority
JO
Jordan
Prior art keywords
heteroaryl compounds
tetracyclic heteroaryl
tetracyclic
relates
compounds
Prior art date
Application number
JOP/2020/0281A
Other languages
English (en)
Inventor
Frederick Woolf Goldberg
Scott Gibson Lamont
Sharanjeet Kaur Bagal
Shaun Michael Fillery
Andrew John Eatherton
Graeme Richard Robb
Paul David Kemmitt
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20200281A1 publication Critical patent/JOP20200281A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بالصيغة (I) وأملاح مقبولة صيدلانياً منها. تتعلق المواصفة أيضاً بعمليات ومركبات وسيطة تستخدم لتحضيرها، تركيبات صيدلانية تحتوي عليها واستخدامها في معالجة اضطرابات تكاثر الخلية.
JOP/2020/0281A 2018-05-08 2019-05-07 مركبات أريل غير متجانسة رباعية الحلقة JOP20200281A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668321P 2018-05-08 2018-05-08
US201862754814P 2018-11-02 2018-11-02
PCT/EP2019/061754 WO2019215203A1 (en) 2018-05-08 2019-05-07 Tetracyclic heteroaryl compounds

Publications (1)

Publication Number Publication Date
JOP20200281A1 true JOP20200281A1 (ar) 2020-11-05

Family

ID=66484036

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0281A JOP20200281A1 (ar) 2018-05-08 2019-05-07 مركبات أريل غير متجانسة رباعية الحلقة

Country Status (23)

Country Link
US (1) US11407765B2 (ar)
EP (1) EP3790884A1 (ar)
JP (1) JP7138724B2 (ar)
KR (1) KR20210006948A (ar)
CN (1) CN112074520A (ar)
AU (1) AU2019267008B2 (ar)
BR (1) BR112020021467A2 (ar)
CA (1) CA3098261A1 (ar)
CL (1) CL2020002866A1 (ar)
CO (1) CO2020013564A2 (ar)
CR (1) CR20200532A (ar)
DO (1) DOP2020000201A (ar)
EC (1) ECSP20070854A (ar)
JO (1) JOP20200281A1 (ar)
MA (1) MA52560A (ar)
MX (1) MX2020011910A (ar)
NI (1) NI202000078A (ar)
PE (1) PE20211795A1 (ar)
PH (1) PH12020551870A1 (ar)
SG (1) SG11202010953QA (ar)
TW (1) TW202012415A (ar)
UY (1) UY38221A (ar)
WO (1) WO2019215203A1 (ar)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
BR112021017408A2 (pt) * 2019-03-05 2022-01-18 Astrazeneca Ab Compostos tricíclicos fundidos úteis como agentes anticancerosos
JP7280975B2 (ja) * 2019-04-28 2023-05-24 ▲勁▼方医▲薬▼科技（上海）有限公司 オキサアザキナゾリン－７（８ｈ）－ケトン化合物、その調製方法及びその医薬用途
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN114828964B (zh) * 2019-12-11 2023-11-24 伊莱利利公司 Kras g12c抑制剂
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685531A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
KR20230145078A (ko) * 2021-02-09 2023-10-17 제넨테크, 인크. 테트라시클릭 옥사제핀 화합물 및 이의 용도
CN117083280A (zh) * 2021-03-07 2023-11-17 北京加科思新药研发有限公司 Kras g12d抑制剂的稠环衍生物
US20240174691A1 (en) * 2021-03-17 2024-05-30 Genfleet Therapeutics (Shanghai) Inc. Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN117083279A (zh) * 2021-04-08 2023-11-17 基因泰克公司 氧氮杂䓬化合物及其在癌症治疗中的用途
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
KR20240024903A (ko) * 2021-06-21 2024-02-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 융합된 사환식 화합물, 이에 대한 제조 방법 및 의학에서 이의 적용
EP4365176A1 (en) * 2021-07-02 2024-05-08 Shanghai de Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
CN117677624A (zh) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
AU2022314009A1 (en) * 2021-07-23 2024-01-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202322819A (zh) 2021-10-22 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
TW202325298A (zh) * 2021-11-01 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN118434422A (zh) 2021-12-28 2024-08-02 阿斯利康(英国)有限公司 抗体-药物缀合物和rasg12c抑制剂的组合
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN114539073A (zh) * 2022-02-18 2022-05-27 郑州萃智医药科技有限公司 3-溴-2-氯-4,6-二氟苯胺的合成方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024031088A1 (en) * 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024063578A1 (ko) * 2022-09-23 2024-03-28 일동제약(주) 신규한 테트라헤테로사이클 화합물
WO2024063576A1 (ko) * 2022-09-23 2024-03-28 일동제약(주) Kras 저해 물질로서 신규한 퀴나졸린 화합물
WO2024085661A1 (en) * 2022-10-18 2024-04-25 Ildong Pharmaceutical Co., Ltd. Novel triheterocyclic compounds
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof
WO2024131829A1 (zh) * 2022-12-20 2024-06-27 江苏恒瑞医药股份有限公司 一种kras g12d抑制剂的结晶形式及制备方法
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024153119A1 (en) * 2023-01-18 2024-07-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2014239542A1 (en) 2013-03-15 2015-10-01 Araxes Pharma Llc Covalent inhibitors of KRas G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
KR20180005178A (ko) 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
EP3325447A1 (en) 2015-07-22 2018-05-30 Araxes Pharma LLC Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
RS62456B1 (sr) 2016-12-22 2021-11-30 Amgen Inc Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
CN110382483A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的n-杂环化合物及其使用方法
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
EP3621968A1 (en) 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
TW201938561A (zh) 2017-12-08 2019-10-01 瑞典商阿斯特捷利康公司 化學化合物
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物

Also Published As

Publication number Publication date
NI202000078A (es) 2021-02-16
US20210221823A1 (en) 2021-07-22
CR20200532A (es) 2020-12-23
UY38221A (es) 2019-10-31
AU2019267008B2 (en) 2022-02-17
SG11202010953QA (en) 2020-12-30
CO2020013564A2 (es) 2020-11-10
MA52560A (fr) 2021-03-17
WO2019215203A1 (en) 2019-11-14
CL2020002866A1 (es) 2021-02-12
PH12020551870A1 (en) 2021-07-26
CA3098261A1 (en) 2019-11-14
CN112074520A (zh) 2020-12-11
JP7138724B2 (ja) 2022-09-16
EP3790884A1 (en) 2021-03-17
TW202012415A (zh) 2020-04-01
BR112020021467A2 (pt) 2021-01-19
AU2019267008A1 (en) 2021-01-07
US11407765B2 (en) 2022-08-09
MX2020011910A (es) 2021-01-29
ECSP20070854A (es) 2020-12-31
PE20211795A1 (es) 2021-09-09
JP2021532061A (ja) 2021-11-25
KR20210006948A (ko) 2021-01-19
DOP2020000201A (es) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CR20210504A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12019501724A1 (en) Estrogen receptor modulators
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
TW201613864A (en) Novel compounds
PH12021550048A1 (en) Selective estrogen receptor degraders.
CR20240160A (es) Compuestos espirocíclicos
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
EA202092600A1 (ru) Тетрациклические гетероарильные соединения
EA201991734A1 (ru) Модуляторы рецептора эстрогена
EA201990943A1 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
EA202192366A1 (ru) Конденсированные трициклические соединения, применимые в качестве противораковых средств